Orthocell Ltd

Orthocell CEO and MD Paul Anderson was named a National Finalist in the Technology category of the prestigious EY Entrepreneur Awards, held in Sydney last week. This is a tremendous honour, recognising his vision, perseverance, and leadership in Australia’s growing regenerative medicine and biotechnology sector. We extend our congratulations to the category winner, Ben Thompson, founder and CEO of Employment Hero, and all the national finalists recognised for their contribution to Australia’s innovation landscape. Watch the video below to learn more about Paul’s journey.   $OCC #Orthocell #biotech #innovation #entrepreneurship #leadership #EOY #EOYAustralia #25YearsofEOY

The American Society for Surgery of the Hand (ASSH) Annual Meeting in Vancouver earlier this month brought together clinicians, scientists and innovators who share a commitment to improving outcomes in peripheral nerve repair.    For the Orthocell team, it was a valuable opportunity to showcase Remplir™, our next-generation collagen nerve wrap, and engage in focused conversations about Remplir’s science, surgical handling and clinical use across different surgical settings.    A key highlight was our Industry Forum, moderated by Dr Amy Moore and featuring expert panellists Dr Ryan Schmucker, Dr Alex O’Beirne and Professor Ming Hao Zheng. The discussion brought together perspectives from material science, emerging US clinical experience and long-term Australian outcomes, offering insights on how Remplir is being applied in practice and evaluated in evolving surgical decision-making.    In partnership with Mosher Medical, we co-hosted a surgeon reception that created opportunities to share real-world experience with Remplir in US clinical practice, and we were equally proud to support the Women in Hand Surgery event, reflecting our commitment to collaboration, diversity and the exchange of ideas that advance the field.    A sincere thank you to all the clinicians who visited our booth, shared their perspectives or took time to discuss complex cases – your expertise continues to shape how Remplir supports clinical practice.    $OCC #Orthocell #Remplir #ASSH2025 #nerverepair #innovation #medtech #medicaldevice   

Orthocell has signed a Memorandum of Understanding to increase its equity stake in Marine Biomedical - from 1.7% to 12.0% for a total consideration of AU$1.0 million - securing exclusive first right of refusal over global distribution rights their groundbreaking bone substitute product, PearlBone™.    Developed using sustainably sourced pearl shells from the West Australian Kimberley coast, PearlBone is an innovative, next-generation biomaterial with promising applications in bone repair and regeneration in the orthopaedic, trauma and reconstructive surgery market.     Marine Biomedical is well advanced in its path to US regulatory approval of PearlBone, nearing completion of its pivotal study designed to support a U.S. FDA 510(k) marketing submission in 1Q CY26 to commercially distribute PearlBone into the US$1.6 billion bone substitute market.    Orthocell Chair, John Van Der Wielen, said:     “This partnership delivers exactly what we look for — breakthrough science, a clear regulatory path, and immediate commercial synergy. With our strong surgeon relationships and global distribution channels, we are ideally positioned to bring this first-in-class product to market. Marine Biomedical has had significant grant support from the Western Australian Government and has been working for many years on the development of this product.”    🔗 Read the ASX release: bit.ly/42R8W0V   $OCC #Orthocell #regenerativemedicine #bonerepair #orthopaedics #invest

Capital Raise Orthocell has today announced that it has received firm commitments for a $30 million capital raising via an institutional placement.  The capital raising received strong international and domestic demand from institutional and sophisticated investors, resulting in the addition of several US institutions to the share register. Canaccord Genuity acted as Sole Lead Manager to the Placement. Proceeds from the raising will be used to: ✅ accelerate the US roll out of the Company’s flagship nerve repair product Remplir™ ✅ undertake clinical studies to commercialise the use of Remplir in the significant prostate cancer surgery market ✅ advance commercialisation of pipeline products in tendon and ligament repair ✅ expand capacity at Orthocell’s existing manufacturing facility ✅ invest in new applications and technologies in the regenerative medicine sector. Orthocell CEO and MD, Paul Anderson, said: “We have built significant momentum in the commercialisaiton of Remplir and the funds from the capital raising will be focused on accelerating that process. We greatly appreciate the support we have received from new and existing institutional and high net worth investors and particularly welcome our new investors from the US. We see that as a significant endorsement of our strategy and progress to date as well as the near-term revenue that can be generated from the US market.” 🔗 Read the ASX release: https://bit.ly/4qgoHbP $OCC #Orthocell #regenerativemedicine #innovation #capitalraise #invest #nerverepair #global

We are proud to share that Orthocell Founder and CEO Paul Anderson has been named a National Finalist in the 2026 Ernst & Young Entrepreneur of the Year Awards, representing Western Australia in the Technology category.    This prestigious program celebrates visionary leaders who challenge convention, create opportunities and shape the future – qualities that have defined Paul’s leadership from Orthocell’s earliest days.    Paul has guided Orthocell from its origins as a university spin-out to becoming a globally recognised regenerative medicine company. Under his leadership, Orthocell has developed and commercialised world-first medical devices that are transforming patients’ lives and strengthening Australia’s manufacturing and biotechnology capability.    National judging takes place today in Sydney, with winners announced at tomorrow night’s Gala event.    A cornerstone of Paul’s leadership is to take calculated and creative risk to not only innovate, but to do so with a commitment to sustainable business principles and unwavering care for the clinicians and patients that Orthocell exists to support.    The whole Orthocell team and our wide community of supporters wish to congratulate you Paul, and to share our appreciation to EY for continuing to champion Australian innovation and entrepreneurship.    $OCC #Orthocell #biotech #innovation #entrepreneurship #leadership #EOY #EOYAustralia #25YearsofEOY 

Orthocell has today released its Quarterly Report for the period ended 30 September 2025, outlining a period of continued growth and strong commercial progress.    Key highlights for the quarter include:  - Record revenue for the quarter of $3.0 million driven primarily by Remplir’s growing market penetration in Australia and Singapore   - Orthocell maintains robust cash reserves of $27 million in cash as at 30 September 2025 and is well-positioned for continued commercial expansion  - Remplir rollout in the US$1.6 Billion US market ahead of schedule, with Distribution networks now spanning 25 states and reaching 40% of the US population, and first surgeries complete   - First distributor appointed for Remplir in US$75 million Canadian market, with first sales targeted for December 2025 Quarter  - Remplir used in nerve-sparing prostate cancer surgery   - Remplir study results deliver compelling 81% success rate  - Strengthened leadership with Executive and Board appointments    Orthocell CEO and MD, Paul Anderson, said:   “We have continued to build strong commercial momentum in the September quarter with another record quarter of sales revenue delivered primarily from Remplir sales in our existing markets in Australia and Singapore.”    Read the ASX release: https://bit.ly/46KnFgx    $OCC #Orthocell #nerverepair #innovation #regenerativemedicine #growth #ASX 

Did you catch Chairman John Van Der Wielen’s recent interview on Proactive? Following Orthocell’s outstanding revenue announcement, he reflected on the Company’s record $3 million quarter — marking six consecutive quarters of growth across Australia, New Zealand and Singapore. John also highlighted the accelerating U.S. rollout and the Company’s expanding global footprint, with its first Canadian distributor appointed, progress underway in Thailand and Hong Kong, and strong growth potential as these markets come online. “It's the sixth quarter in a row that we've displayed growth, and for investors, we're very confident that will continue. The most important part about the result is it mainly relates to Australia, New Zealand and Singapore, with some early activity in the US, but a lot more to come.” Take a look 👉 https://bit.ly/4pSj3fL $OCC #Orthocell #nerverepair #Remplir #innovation #medtech #revenue #growth

📈 Record Growth Continues    Orthocell has announced record quarterly revenue of $3.0 million for the September quarter – our sixth consecutive quarter of record revenue growth.    This outstanding 9.1% increase reflects the strong market uptake of Remplir™ in Australia and Singapore, with the US rollout now gaining momentum and Canada coming online in the December quarter.    Key Highlights:  ✅ Record quarterly revenue of $3.0m (up 9.1% from June quarter)  ✅ Sixth consecutive quarter of record revenue  ✅ CQGR of 9.5% since Q2 FY23 launch  ✅ ~$27.0m cash and no debt  ✅ US rollout accelerating with >100 surgeons introduced & 11 hospital approvals secured  ✅ First Canadian distributor appointed – initial sales targeted for December quarter    Orthocell CEO & MD, Paul Anderson, said:  “The record revenue result for the September quarter is a particularly pleasing result, given it has largely been achieved from our existing markets in Australia and Singapore.  It’s a tangible confirmation that surgeons are growing increasingly comfortable using Remplir in nerve repair procedures.” Read today’s ASX release 👉 https://bit.ly/4mGtZKR   $OCC #remplir #regenerativemedicine #nerverepair #medtech #growth #innovation #recordrevenue 

Industry Forum | Charting the Future of Nerve Repair with Remplir™  Orthocell is proud to be hosting an Industry Forum at the 80th Annual Meeting of the American Society for Surgery of the Hand (ASSH) next month in Vancouver, Canada.    The session will explore how Orthocell’s novel collagen device, Remplir™, is advancing the field of peripheral nerve repair and addressing critical gaps in surgical care.    Moderated by Dr Amy Moore, Professor and Chair of Plastic and Reconstructive Surgery at The Ohio State University, the session will feature a distinguished faculty of global experts: - Dr Ryan Schmucker, Clinical Assistant Professor of Plastic and Reconstructive Surgery, The Ohio State University - Dr Alex O’Beirne, Orthopaedic Surgeon, Western Orthopaedic Clinic, Perth, Australia - Professor Ming Hao Zheng, Academic Pathologist, The University of Western Australia 📍 Location: 220-222, Level 2, Vancouver Convention Centre  🗓️ Date: Friday, 10 October  ⏰ Time: 11:45 am – 12:45 pm PDT    Join us as we explore the future of nerve repair and the expanding potential of Remplir™ to improve surgical outcomes for patients worldwide.    $OCC #Orthocell #medtech #nerverepair #medicaldevice #orthopaedics #innovation #ASSH2025 

📰 Stockhead   Orthocell was featured in Stockhead last week, in an article by leading biotech journalist tim boreham titled “Orthocell flags rapid ‘hockey stick’ revenue growth in the US$1.6 billion US nerve repair market.”    The article explores our global expansion, including the rapid rollout of Remplir in the US following FDA clearance, new international markets such as Canada and Asia, and emerging opportunities in prostate surgery. It also highlights the Company’s strong financial position as we scale globally.    Here’s an excerpt:    “Van Der Wielen notes Orthocell’s revenue has grown at an average annual compound rate of 34% over the past three years. The company is “not too far from heading to profit” as US revenues flow in.    “We are at an inflexion point,” Van Der Wielen says. “We expect to see revenue rates sustainably increase. We are very much focused on the US and couldn’t be happier with the progress and the quality of people we already have employed.”    It’s worth a read 👉 https://lnkd.in/gFwcdAHE    $OCC #Orthocell #innovation #nerverepair #globalexpansion Stockhead